摘要
为了检测从野生草食动物临床标本中分离的62株奇异变形杆菌对23种抗菌药物的体外活性以及这些杆菌产生超广谱β-内酰胺酶、AmpC酶、金属β-内酰胺酶的情况,正确指导兽医临床合理使用抗菌药物。用API-20E对分离获得的菌株进行鉴定,双纸片协同试验和确证试验筛选超广谱β-内酰胺酶,纸片扩散法检测AmpC酶,改良Hodge试验检测金属β-内酰胺酶,药敏试验采用标准的纸片扩散法。实验证实分离获得的奇异变形杆菌产酶率为25.8%(16/62),其中超广谱β-内酰胺酶为16.1%(10/62),AmpC酶为9.7%(6/62)、金属β-内酰胺酶为0%(0/62)。头孢曲松钠、头孢他啶、头孢吡肟、氨曲南、亚胺培南、头孢噻肟钠、丁胺卡那霉素和左氧氟沙星的敏感率大于80%。这说明产β-内酰胺酶的奇异变形杆菌在野生草食动物临床中占较大的比例,实验室需加强检测。三代头孢菌素、四代头孢菌素、氨曲南、亚胺培南、丁胺卡那霉素和左氧氟沙星是治疗奇异变形杆菌感染的首选药物。
Drug resistance of 62 strains of Proteus mirabilis,isolated from clinical specimen of wild herbivores against 22 kinds of antibiotics was tested for their production ofβ-lactamase,extended spectrumβ-lactamase,AmpC lactamase and metalloβlactamase.Methods used in the analysis were API-20E for identification of bacterium strains isolated;the double synergy test and phynotypic conformatory test for screening extended spectrumβ-lactamase;disk diffusion method for determining AmpCβ-lactamase;the modified Hodge test for determining metalloβ-lactamase;the standard disc diffusion method for determining susceptibility of different strains.Data of results were as follows：16 strains producingβ-lactamase, 25.8%;10 strains producing extended spectrumβ-lactamase,16.1%;6 strains producing AmpCβ-lactamase 9.7%; no strains producing mettalloβ-lactamase,0%.Resistance to antibiotics〈20%;drugs for the first choice were third generation cephalosporin,fourth generation cephalosporin,azlreonam,imipenem,amikacin ticacilin/CA and levofloxacin.
出处
《野生动物》
2010年第5期249-251,253,共4页
